Edward’s Syndrome Market

Market Overview:

The 7 major Edward’s syndrome markets reached a value of US$ 3.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7.6 Billion by 2034, exhibiting a growth rate (CAGR) of 7.51% during 2024-2034.

The Edward’s syndrome market has been comprehensively analyzed in IMARC's new report titled "Edward’s Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Edward's syndrome, also known as Trisomy 18, refers to a rare genetic disorder that occurs due to the presence of an additional chromosome 18 copy. This disease results in severe developmental abnormalities and is associated with a high rate of miscarriages and stillbirths. It more commonly develops in females than males. The symptoms of the syndrome are varied and can include low birth weight, small head size, clenched fists with overlapping fingers, heart defects, kidney malformations, and characteristic facial features, such as a small jaw and low-set ears. Individuals suffering from the illness often experience intellectual disabilities and growth delays, leading to a poor overall prognosis. Diagnosing Edward's syndrome typically involves prenatal screening tests, such as ultrasound and maternal serum screening, to assess the risk of chromosomal abnormalities. A definitive diagnosis is made through genetic testing, usually using a sample of amniotic fluid or chorionic villus cells obtained through amniocentesis or chorionic villus sampling (CVS).

The escalating prevalence of somatic mutations in the GNAQ gene, resulting in the presence of an extra copy of chromosome 18 that can further cause various physical and developmental abnormalities, is primarily driving the Edward's syndrome market. In addition to this, the rising adoption of effective medical interventions, including supportive care and specialized treatments, like physical and occupational therapies, is also contributing to a positive market outlook. Moreover, the inflating utilization of targeted medications, such as antiepileptic drugs and surgical procedures to manage complications, is further bolstering market growth. Additionally, the growing prominence of advanced genetic therapies, like gene editing techniques, since they hold promising potential for correcting or replacing the malfunctioning genes responsible for Edward's syndrome, is acting as another significant growth-inducing factor. Furthermore, the increasing awareness among medical professionals and caregivers about early diagnosis and intervention is also augmenting the market growth. Apart from this, numerous supportive initiatives from governments and healthcare organizations aimed at promoting research and development in the field of genetic disorders are creating a conducive environment for market expansion. Additionally, the emerging popularity of surgical procedures to correct anatomical defects, such as heart or kidney problems, is expected to drive the Edward's syndrome market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Edward’s syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Edward’s syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Edward’s syndrome market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Edward’s syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Edward’s syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Edward’s syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the Edward’s syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Edward’s syndrome market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Edward’s syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Edward’s syndrome across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Edward’s syndrome by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Edward’s syndrome by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with Edward’s syndrome across the seven major markets?
• What is the size of the Edward’s syndrome patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Edward’s syndrome?
• What will be the growth rate of patients across the seven major markets?
   

Edward’s Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Edward’s syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Edward’s syndrome market?
• What are the key regulatory events related to the Edward’s syndrome market?
• What is the structure of clinical trial landscape by status related to the Edward’s syndrome market?
• What is the structure of clinical trial landscape by phase related to the Edward’s syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the Edward’s syndrome market?